Type

Journal Article

Authors

John Crown
Norma O'Donovan
Denis M Collins
Giuseppe Gullo
Neil A O'Brien
Brigid C Browne
Nicola Gaynor
Kasper Pedersen
Neil T. Conlon
Laura Ivers
and 1 others

Subjects

Medicine & Nursing

Topics
cancer cells patients cancer cell lines inhibitors her2 positive tyrosine kinase breast cancer trastuzumab

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. (2018)

Abstract Despite trastuzumab and pertuzumab improving outcome for patients with HER2-positive metastatic breast cancer, the disease remains fatal for the majority of patients. This study evaluated the anti-proliferative effects of adding anti-HER2 tyrosine kinase inhibitors (TKIs) to trastuzumab and pertuzumab in HER2-positive breast cancer cells. Afatinib was tested alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. TKIs (lapatinib, neratinib, afatinib) combined with trastuzumab and/or pertuzumab were tested in 3 cell lines, with/without amphiregulin and heregulin-1β. Seven of 11 HER2-positive cell lines tested were sensitive to afatinib (IC
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

John Crown, Norma O'Donovan, Denis M Collins, Giuseppe Gullo, Neil A O'Brien, Brigid C Browne, Nicola Gaynor, Kasper Pedersen, Neil T. Conlon, Laura Ivers and 1 others

Experts in our system

1
John Crown
Dublin City University
Total Publications: 104
 
2
Norma O'Donovan
Dublin City University
Total Publications: 59
 
3
Denis M Collins
Dublin City University
Total Publications: 26
 
4
Giuseppe Gullo
Dublin City University
 
5
Neil A O'Brien
Dublin City University
Total Publications: 9
 
6
Brigid C Browne
Dublin City University
Total Publications: 11
 
7
Kasper Pedersen
Dublin City University
Total Publications: 3
 
8
Neil T. Conlon
Dublin City University
Total Publications: 10